Targeting Myeloma Cells

Author: Dr. Ahmed Farhan     Published: 1 year ago 2 Replies

New drugs are being tested for the treatment of Multiple Myeloma to find the least toxic and most potent one.

Let's talk about how these drugs act.

Mezigdomide, a Cereblon E3 ubiquitin ligase modulator, targets  Ikaros and CK1α inhibiting tumor growth.

We need to know more about:

  • Ikaros
  • CK1α

to know about Mezigdomide.

Dr. Ahmed Farhan, 1 year ago

There is a recent study of mezigdomide plus dexamethasone in multiple myeloma patients.primary objectives were to evaluate the safety and efficacy of mezigdomide plus dexamethasone .

results were promising

ck1a

Regulates signaling pathways related to

membrane trafficking,

cell cycle progression,

chromosome segregation,

apoptosis,

autophagy,

cell metabolism, 

differentiation in development,

circadian rhythm(first kinase to have this activity),  immune response 

neurodegeneration

cancer

 

 

MUHAMMAD BILAL AMJAD, 1 year ago

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information

emedz.net

Book Online and In-clinic appointments with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues. Advertisers who wish to place ads on emedz.net and reach multiple users can contact here: ads@emedz.net

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.